Τίτλος:
In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Cefepime/zidebactam is in clinical development for the treatment of carbapenem-resistant Gram-negative infections. MICs of cefepime/zidebactam (1:1) and comparators against Enterobacterales (n = 563), Pseudomonas (n = 172) and Acinetobacter baumannii (n =181) collected from 15 Greek hospitals (2014-2018) were determined by reference broth microdilution method. The isolates exhibited high carbapenem resistance rates [(Enterobacterales (75%), Pseudomonas (75%) and A. baumannii (98.3%)]. Cefepime/zidebactam showed MIC50/90 of 0.5/2 mg/L, against Enterobacterales including metallo-β-lactamases (MBL)-producers. Reduced susceptibility rates to tigecycline (16.8%), colistin (47.4%), ceftazidime/avibactam (59.8%), and imipenem/relebactam (61%) indicated high prevalence of multi-drug resistance among Greek Enterobacterales. Cefepime/zidebactam exhibited MIC50/90 of 8/16 mg/L against Pseudomonas including MBL-producers. The MIC50/90 of ceftazidime/avibactam and imipenem/relebactam were high (≥32 mg/L). Cefepime/zidebactam showed MIC90 of 64 mg/L against A. baumannii which is within its therapeutic scope. Other antibiotics including colistin showed limited activity against A. baumannii. The activity of cefepime/zidebactam against multi-drug-resistant isolates is attributable to zidebactam mediated novel β-lactam-enhancer mechanism. © 2021 Elsevier Inc.
Συγγραφείς:
Bhagwat, S.S.
Legakis, N.J.
Skalidis, T.
Loannidis, A.
Goumenopoulos, C.
Joshi, P.R.
Shrivastava, R.
Palwe, S.R.
Periasamy, H.
Patel, M.V.
Chatzipanagiotou, S.
Hellenic Cefepime/Zidebactam Study Group
Περιοδικό:
Diagnostic Microbiology and Infectious Disease
Εκδότης:
HANLEY & BELFUS-ELSEVIER INC
Λέξεις-κλειδιά:
amikacin; antiinfective agent; avibactam plus ceftazidime; beta lactam antibiotic; carbapenem; carbapenemase; cefepime; cefepime plus zidebactam; cefiderocol; ceftazidime; ceftolozane plus tazobactam; ciprofloxacin; colistin; ertapenem; imipenem; imipenem plus relebactam; meropenem; metallo beta lactamase; piperacillin plus tazobactam; unclassified drug; wck 5222; antiinfective agent; azabicyclo derivative; cefepime; cephalosporin derivative; cyclooctane derivative; piperidine derivative; WCK 5222; zidebactam, Acinetobacter baumannii; antibacterial activity; antibiotic resistance; Article; bacterium isolation; broth dilution; concentration response; controlled study; Enterobacterales; Escherichia coli; Gram negative bacterium; Greece; in vitro study; Klebsiella pneumoniae; MIC50; MIC90; nonhuman; prevalence; Pseudomonas; drug effect; Gram negative bacterium; hospital; human; microbial sensitivity test; multidrug resistance, Anti-Bacterial Agents; Azabicyclo Compounds; Cefepime; Cephalosporins; Cyclooctanes; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Greece; Hospitals; Humans; Microbial Sensitivity Tests; Piperidines
DOI:
10.1016/j.diagmicrobio.2021.115327
